Logo of Mach7 Technologies (ASX:M7T)Latest Mach7 Technologies (ASX:M7T) News

Page 1
Page 1 of 3

Mach7 adds Temple Health to five-year subscription portfolio

Mach7 Technologies has signed Temple Health to a five-year licence for its eUnity Viewer and Vendor Neutral Archive, with Year 1 annual recurring revenue expected to reach A$0.5 million. The revenue will depend on go-live and first productive use, forecast within six to 12 months.
Victor Sage
13 Nov 2026

Mach7’s FY26 reset cuts costs as revenue falls and losses widen

Mach7 Technologies has completed a costly FY26 reset, cutting operating expenditure by 16% while revenue fell 17% and the net loss widened to A$8.9 million. The company enters FY27 with a higher recurring-revenue mix, new customer orders and A$19.9 million in cash, but no earnings guidance and plenty to prove.
Victor Sage
30 Oct 2026

Mach7 turns first-quarter cash flow positive as Flamingo moves towards launch

Mach7 Technologies has delivered its first positive first-quarter operating cash flow, while ARR rose 8.5% in constant currency to A$23.5 million. The next test is whether increased product investment and the Flamingo rollout can translate into contracted sales.
Victor Sage
26 Oct 2026

Mach7 Technologies Posts 17% Revenue Decline Amid Subscription Shift and Cost Restructuring

Mach7 Technologies reported a 17.4% revenue drop to $27.9 million and a 44% increase in net loss to $8.9 million for FY26, driven by a strategic transition to a subscription model and cost base restructuring.
Victor Sage
28 Aug 2026

Mach7 Advances Recurring Revenue and Expands Partner Network Amid Positive Cash Flow

Mach7 Technologies delivered a positive operating cash flow in Q4 FY26, boosted its ARR run rate by 7.6% in constant currency, and secured multi-year subscription deals while expanding its partner ecosystem.
Victor Sage
29 July 2026

Healthcare Wrap - Week 21 (18 May -> 22 May) 2026

Imugene, Vitasora and Adherium led a volatile week in healthcare shares, as trial news and software rollouts battled capital raisings, legal issues and weak sentiment in smaller biotech names. Big contracts, takeover steps and record earnings kept the sector busy, but several stocks still fell even after reporting clear operational progress.
Logan Eniac
23 May 2026

Mach7 Cuts Deployment Time with $1.7M AMRADNET Deal

Mach7 Technologies has secured a five-year, A$1.7 million subscription contract with US teleradiology provider AMRADNET, slashing deployment time from 12 months to just 45 days.
Ada Torres
20 May 2026

Mach7 Technologies Wraps Up $2.24M Share Buy-Back, Buys 6.27M Shares

Mach7 Technologies has completed its on-market share buy-back, acquiring over six million shares at an average price well below the initial $5 million cap. The move signals a cautious but confident approach to capital management amid evolving market conditions.
Victor Sage
4 Mar 2026

Mach7 Technologies Faces Revenue Slide and Loss Surge Amid Strategic Reset

Mach7 Technologies reported a 23% drop in revenue to $13.65 million for H1 FY26, alongside a sharp increase in net loss to $5.75 million, as it embarks on a strategic commercial reset and expands its Asia-based engineering capabilities.
Victor Sage
27 Feb 2026

Mach7 Technologies Secures First Flamingo Contract Amid Positive Cash Flow Turnaround

Mach7 Technologies reports a positive operating cash flow in Q2 FY26, securing its first customer for the new Flamingo Architecture product and advancing key strategic initiatives.
Victor Sage
30 Jan 2026

VHA Halts NextGen PACS Program, Mach7 Faces Contract Setback

Mach7 Technologies has been notified that the Veterans Health Administration will cease its NextGen PACS program, leading to a partial stop work order and cancellation of Phase 2 of the contract. Despite this, Mach7 remains focused on its broader commercial strategy.
Victor Sage
23 Jan 2026

Mach7 Secures $1M ARR Deal with UnityPoint Health for Flamingo Architecture

Mach7 Technologies has inked a five-year subscription agreement with UnityPoint Health, marking the first commercial deployment of its new Flamingo Architecture and setting the stage for significant recurring revenue growth.
Victor Sage
3 Dec 2025